MIRA Pharmaceuticals reports that its oral ketamine analog, Ketamir-2, demonstrated significantly greater efficacy than FDA-approved treatments Gabapentin and Pregabalin in recent preclinical models of neuropathic pain. The company is conducting additional studies on chemotherapy-induced and diabetic neuropathy, while also planning PTSD trials.MIRA remains on track to submit an Investigational New Drug (IND) application by end-2024, with Phase I clinical trials expected to begin in Q1 2025 and Phase II trials projected to start by late 2025. The company is exploring government funding opportunities to support the PTSD program.This announcement contains forward-looking statements. Actual results may differ materially from those anticipated. MIRA does not assume any obligation to update these statements as circumstances change, except as required by securities laws.

MIRA Pharmaceuticals reports that its oral ketamine analog, Ketamir-2, demonstrated significantly greater efficacy than FDA-approved treatments Gabapentin and Pregabalin in recent preclinical models of neuropathic pain. The company is conducting additional studies on chemotherapy-induced and diabetic neuropathy, while also planning PTSD trials.MIRA remains on track to submit an Investigational New Drug (IND) application by end-2024, with Phase I clinical trials expected to begin in Q1 2025 and Phase II trials projected to start by late 2025. The company is exploring government funding opportunities to support the PTSD program.This announcement contains forward-looking statements. Actual results may differ materially from those anticipated. MIRA does not assume any obligation to update these statements as circumstances change, except as required by securities laws.